守护人类健康，创新生物制药
Zhifeishengwu (zhifeishengwu.com) earns a Brand Analyzer score of 49 out of 100, placing it in the Early Stage tier among Healthcare brands, Technology brands. Among 2305 Healthcare brands analyzed, Zhifeishengwu ranks in the 3rd percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 77/100, Digital Presence 65/100, Visual Identity 94/100, Messaging Clarity 53/100, Trust Foundation 47/100, AI Discoverability 24/100, Brand Authority 7/100.
Zhifeishengwu (重庆智飞生物制品股份有限公司) is a Chongqing-based biopharmaceutical company established in 2002, specializing in vaccines and biological products. It covers research, development, production, sales, distribution, and import/export across the full industry chain. With registered capital of 1.6 billion yuan, approximately 2,400 employees, and assets of 6.2 billion yuan, the company listed on Shenzhen's ChiNext board in September 2010 (stock code: 300122), becoming the first privately-owned vaccine enterprise listed on that exchange.
| Brand Name | Zhifeishengwu |
|---|---|
| Domain | zhifeishengwu.com |
| Industry | Healthcare, Technology |
| Founded | 2002 |
| Headquarters | Chongqing, China |
| Main Competitors | China National Biotec Group (CNBG), Sinovac Biotech, Walvax Biotechnology, CanSino Biologics, Shenzhen Kangtai Biological Products |
Moz Domain Authority 26/100 vs category average 29 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "重庆智飞生物制品股份有限公司（简称“智飞”或“智飞生物”）2002年投入生物制品行业，注册资金16亿元，现有员工2400余人，资产62亿元，2010年9月在深交所挂牌上市（股票代码：300122），成为第一家在创业板上市的民营疫苗企业，旗下五家全资子公司及一家参股子公司，其中北京智飞绿竹生物制药有限公司（简称“北京智飞绿竹”）及安徽智飞龙科马生物制药有限公司…" (Meta description too short (1 words). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Instagram; no detected presence on X (Twitter), LinkedIn, Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Zhifeishengwu scores 12/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Zhifeishengwu has a weak AI-visibility profile at 12/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (27/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 26/100.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Zhifeishengwu's main competitors include China National Biotec Group (CNBG), Sinovac Biotech, Walvax Biotechnology, CanSino Biologics, Shenzhen Kangtai Biological Products. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Zhifeishengwu official site
Zhifeishengwu (重庆智飞生物制品股份有限公司), commonly known as 'Zhifei' or 'Zhifei Biological,' is a Chinese biopharmaceutical company founded in 2002 and headquartered in Chongqing. It entered the biological products industry upon its founding, has registered capital of 1.6 billion yuan, and employs over 2,400 people. It became publicly listed on the Shenzhen Stock Exchange's ChiNext board in September 2010 (stock code: 300122), making it the first privately-owned vaccine enterprise to list on that board. It operates five wholly-owned subsidiaries and one equity-participation subsidiary.
Sources: Zhifeishengwu official site
Zhifeishengwu is engaged in the research, development, production, sales, distribution, and import/export of vaccines and biological products. It operates as an internationalized, full-industry-chain biopharmaceutical enterprise driven by a dual 'technology and market' model, which creates a mutually reinforcing relationship between market activities and research and development. Its mission is to prevent disease before it occurs and treat disease after onset, with the goal of becoming a world-class biopharmaceutical company.
Sources: Zhifeishengwu official site
Popular alternatives to Zhifeishengwu include China National Biotec Group (CNBG), Sinovac Biotech, Walvax Biotechnology, CanSino Biologics, Shenzhen Kangtai Biological Products. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Zhifeishengwu official site
Zhifeishengwu has low AI-search visibility, scoring 12/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 19, recommendation 27). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Zhifeishengwu official site
Zhifeishengwu's portfolio encompasses vaccines and biological products, covering the full spectrum from research and development to production and commercial distribution. The company also engages in the import and export of biological products, suggesting its offering includes both domestically developed and internationally sourced vaccines and biologics. Its subsidiaries Beijing Zhifei Lvzhu and Anhui Zhifei Longcom are designated high-technology enterprises involved in biopharmaceutical production. Specific product names or individual vaccine types are not detailed in the available facts.
Sources: Zhifeishengwu official site
Zhifeishengwu and China National Biotec Group (CNBG) are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Zhifeishengwu official site
Zhifeishengwu is primarily known for being the first privately-owned vaccine enterprise to list on Shenzhen's ChiNext board (创业板) in September 2010. It is also recognized as a full-industry-chain biopharmaceutical company covering vaccines and biological products from R&D through distribution and import/export. Two of its subsidiaries-Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.-have been designated high-technology enterprises, further underscoring its standing in China's biotech sector.
Sources: Zhifeishengwu official site
Zhifeishengwu scores 27/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Zhifeishengwu official site
Zhifeishengwu can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Zhifeishengwu official site
According to the available information, Zhifeishengwu's target audience includes medical institutions, patients, and global health-need populations. As a company operating in the vaccine and biological products sector with import and export activities, its customers and end users span domestic healthcare providers and patients in China as well as international markets. The company's mission of 'guarding human health' through disease prevention and treatment suggests its products are directed toward broad public health applications rather than any narrow demographic segment.
Sources: Zhifeishengwu official site
Zhifeishengwu's prominence stems from its position as the first privately-owned vaccine company listed on Shenzhen's ChiNext board, giving it a distinctive market profile among Chinese biopharmaceutical firms. Its integrated, full-industry-chain business model-spanning R&D, production, sales, distribution, and international trade-and its dual 'technology and market' driving strategy are cited as core competitive strengths. The company's stated mission of protecting human health through disease prevention and treatment also aligns with broad public health priorities, contributing to its recognition in China's vaccine market.
Sources: Zhifeishengwu official site
Ranked closest to Zhifeishengwu: Careington (49/100), ServingIntel (49/100), Breckenridge Pharmaceutical (48/100), Circulo Health (48/100).
A step up - brands to learn from: Werskincare (56/100), Virtue TCM 醫道閣 (56/100).
Category leader: Dassault Systèmes (95/100).